The Cannabis Sector and Its Dot-Com Like Meltdown

Black-market vaping has made the entire cannabis group toxic.

Analysts Puffed, Now Passing on Canopy Growth

What is the green swan that will bring buyers back to cannabis companies?

Kass: Time to Buy Cannabis Stocks for a Trade -- And Soon for a LT Investment

I'm considering establishing a long investment stake in a package of cannabis stocks, with emphasis on U.S.-based companies.

Cannabis Players All Remember Tilray but Will They Become Buyers Again?

This looks like a good opportunity to take a fresh look at the charts and indicators of the former 'high flyer'.

Jim Cramer: Let's Wait for Full Story on Promising GW Pharma Drug

After a negative report on GW's epilepsy treatment, the analyst refused to explain the results with me, bringing more questions than answers about its conclusions.

GW Pharmaceuticals Could Fall Another 30% From Here

Shares of the cannabinoid prescription medicine company look to be in a weak state.

The Charts of Canopy Growth Are Missing Signs of Accumulation for Now

Let's go to the charts and indicators.

Cronos Group Is Still Coming Down From Its High

Shares of the cannabis company are likely to drift lower in the weeks ahead.

John Legend Is High on a CBD Startup Called Plus Products

Singer teamed up with company this week, sending its stock on a wild ride.

Massachusetts Slow Roll Causes Cannabis Companies to Adjust Plans

A cautious approach by the state is having a wicked effect on earnings and estimates.